Latest | Instant Finance & Market News_第84页 | NewTimeSpace

09:49

[ CSOP Hang Seng HK-US TECH ETF (03442.HK) Rises 2.86% in Morning Trade, Latest Price at HKD 8.080 ] As of September 4 at 09:48, CSOP Hang Seng HK-US TECH ETF (03442.HK) rose 2.86%, with a latest price of HKD 8.080.

Tag： 03442.HK ETF CSOP Hang Seng HK-US TECH ETF

09:44

[ ETF Financing Ranking | China Southern CSI 500 ETF (510500) had a net financing buy-in of CNY 47.32 million on Sep 3 ] NewTimeSpace (newtimespace.com) News,Sep 3, 2026, China Southern CSI 500 ETF (510500.SH) had a net financing buy-in of CNY 47.32 million.

Tag： China Southern CSI 500 ETF 510500.SH NewTimeSpace

09:29

[ DUFU LIQUOR GP (00986.HK) plans to issue up to 25.89 million shares by placement, with estimated net proceeds of HKD 6.5 million ] DUFU LIQUOR GP (00986.HK) plans to issue up to 25.89 million shares by placement, with estimated net proceeds of HKD 6.5 million.

Tag： DUFU LIQUOR GP 00986.HK NewTimeSpace

09:24

[ NEW CONCEPTS (02221.HK) plans to issue in total 14.89 million shares ] NEW CONCEPTS (02221.HK) plans to issue in total 14.89 million shares.

Tag： NEW CONCEPTS 02221.HK NewTimeSpace

08:41

[ GENSCRIPT BIO (01548.HK): Proposes spin-off and separate listing of Probio Technology on the Main Board ] On 4 September 2026, GENSCRIPT BIO (01548.HK) announced a proposal to spin off and separately list its indirect non-wholly-owned subsidiary Probio Technology (its biologics and advanced therapies CDMO business) on the Main Board of HKEX, with the Listing Committee having confirmed on 14 August 2026 that the Company may proceed; the Company will retain a controlling interest upon completion, eligible shareholders will be offered a guaranteed allocation, and the spin-off may or may not proceed.

Tag： GENSCRIPT BIO 01548.HK Separate Listing

08:37

[ H WORLD-S (01179.HK): Proposes offshore offering of RMB-denominated bonds outside the United States ] On 4 September 2026, H WORLD-S (01179.HK) announced a proposed offering of RMB-denominated bonds to non-US persons in offshore transactions under Regulation S of the US Securities Act, with the principal amount, interest rate and maturity to be determined at pricing; the net proceeds are intended for general corporate purposes, and the bonds will not be registered under the Securities Act, with no assurance that the offering will be completed.

Tag： HWORLD-S 01179.HK Debt Offering

08:35

[ INSILICO (03696.HK): Chairman launches share purchase plan in September, up to HKD 16 million ] On 4 September 2026, INSILICO (03696.HK) announced that chairman and chief executive officer Dr. Aleksandrs Zavoronkovs has initiated a plan to purchase additional shares on the open market with his personal funds during September 2026, with an estimated aggregate amount of up to HKD 16 million; the Company is expected to maintain a sufficient public float after implementation of the plan.

Tag： Insilico 03696.HK Share Increase

08:29

[ SALUBRIS files for listing on HKEX: the second largest in China by 2025 hospital sales of cardiovascular drugs, with innovative drugs accounting for over half of revenue ] On 3 September 2026, SALUBRIS filed its listing application with HKEX, with Goldman Sachs, Citigroup and CITIC Securities as joint sponsors; according to Frost & Sullivan, the Company ranked second in China by 2025 in-hospital sales of cardiovascular drugs (with an 11.3% market share) and second among domestic enterprises by the number of CKM syndrome pipeline candidates; in 2025, CKM syndrome drug revenue reached RMB 2,899.1 million, with innovative drugs accounting for 52.1% of revenue.

Tag： SALUBRIS IPO file a listing application

08:20

[ EDICO HOLDINGS (08450.HK): Supplemental disclosure on trading card business controls and media clarification, financial printing remains core business ] On 3 September 2026, EDICO HOLDINGS (08450.HK) made supplemental disclosures on its trading card business: confirming that financial printing remains the Group's principal business (no scaling-down plan within the next 12 months, with interim revenue up 47.1% to approximately HKD 12.6 million), disclosing internal control measures and funding caps for HKTCG, and clarifying media reports that the approximately HKD 80 million of cards displayed include personal collections still owned by their owners, and that the approximately HKD 60 million represents an estimate of potential resources for HKTCG's future development rather than an actual capital contribution.

Tag： EDICO HOLDINGS 08450.HK Business Development

08:04

[ HENGRUI PHARMA (01276.HK): NMPA approves oteseconazole capsules for marketing in China for severe vulvovaginal candidiasis ] On 3 September 2026, HENGRUI PHARMA (01276.HK) announced that the NMPA has approved the domestic registration and marketing of oteseconazole capsules (0.15g, Class 4 chemical drug) developed by its subsidiary Chengdu Shengdi, for the treatment of severe vulvovaginal candidiasis (VVC); the drug is an oral small-molecule fungal CYP51 inhibitor introduced from the US company Mycovia, and this approval covers the transfer of the overseas-produced drug to domestic production.

Tag： HENGRUI PHARMA 01276.HK Drug Marketing Authorization

08:02

[ HENGRUI PHARMA (01276.HK): NMPA accepts marketing application for atopic dermatitis antibody Zhuotuoqibai injection ] On 3 September 2026, HENGRUI PHARMA (01276.HK) announced that the NMPA has accepted the marketing application for Zhuotuoqibai injection (SHR-1819), an IL-4Rα-targeting antibody independently developed by its subsidiary Guangdong Hengrui, for moderate to severe atopic dermatitis in adults; the Phase III study (652 patients) met both co-primary efficacy endpoints with results significantly superior to placebo.

Tag： HENGRUI PHARMA 01276.HK New Drug Marketing Application

08:00

[ HENGRUI PHARMA (01276.HK): NMPA accepts marketing application for oral GLP-1 weight-loss drug HRS-7535 tablets ] On 3 September 2026, HENGRUI PHARMA (01276.HK) announced that the NMPA has accepted the marketing application for HRS-7535 tablets, an oral small-molecule GLP-1 receptor agonist developed by its subsidiary Shandong Shengdi, for long-term weight management in adults (obesity or overweight with comorbidities); the pivotal Phase III study showed an average weight reduction of up to 11.1% in the 180mg group at week 50.

Tag： HENGRUI PHARMA 01276.HK R&D Progress

07:54

[ TENCENT MUSIC-SW (01698.HK): Prices USD 1 billion senior unsecured notes offering in two tranches ] On 4 September 2026, TENCENT MUSIC-SW (01698.HK) announced the pricing of its public offering of USD 1 billion senior unsecured notes in two tranches — USD 500 million at 5.050% due 2031 and USD 500 million at 5.650% due 2036 — with expected net proceeds of approximately USD 991.9 million for offshore debt refinancing and share repurchases; the notes are expected to be listed on HKEX.

Tag： TENCENT MUSIC-SW 01698.HK Debt Offering

07:51

[ CIRC (01763.HK): Coupon rate of sci-tech innovation corporate bonds (Tranche 1) set at 1.50% ] On 3 September 2026, CIRC (01763.HK) announced that the coupon rate of its 2026 sci-tech innovation corporate bonds to professional investors (Tranche 1, with an issue size of no more than RMB 500 million and a three-year tenor) has been determined at 1.50% following bookkeeping, with the offline issue scheduled for 4 and 7 September.

Tag： CIRC 01763.HK Debt Offering

07:44

[ SIMCERE PHARMA (02096.HK): RSV preventive biologic Yimule approved for marketing in China ] On 3 September 2026, SIMCERE PHARMA (02096.HK) announced that Yimule (Kulaiweibai injection), a domestic Class 1 innovative biologic developed in strategic cooperation with Ruiyang, has been approved by the NMPA for marketing in China, for the prevention of RSV-associated lower respiratory tract infection in neonates and infants; Phase III data showed 85.32% protective efficacy against RSV-associated lower respiratory tract infection requiring medical intervention and 83.27% against RSV-associated hospitalisation at 150 days after administration.

Tag： SIMCERE PHARMA 02096.HK R&D Progress

07:41

[ GOLDEN FAITH GP (02863.HK): Chairman Ko Chun Hei places entire 17.34% stake ] On 3 September 2026, GOLDEN FAITH GP (02863.HK) announced that chairman and executive director Mr. Ko Chun Hei has placed his entire shareholding of 119,595,000 shares (approximately 17.34%) through a placing agent, and no longer holds any shares after completion; all placees are independent third parties, and no single placee may hold 30% or more of the issued share capital after the placing.

Tag： GOLDEN FAITH GP 02863.HK Placing

07:39

[ GANFENGLITHIUM (01772.HK): VP's reduction plan expires without implementation, holding unchanged at 215,050 shares ] On 4 September 2026, GANFENGLITHIUM (01772.HK) announced that the reduction plan of vice president Mr. Fu Lihua (up to 40,000 shares, during 4 June to 3 September 2026) has expired without implementation, with his holding unchanged at 215,050 shares (0.010% of the total share capital).

Tag： GANFENGLITHIUM 01772.HK Reduction of Holdings

21:31

[ FUTURE BRIGHT (00703.HK): Enters into Two Renovation Contracts for Edo Japanese Restaurant with Aggregate Contract Price of Approximately MOP 14.43 Million ] On September 3, 2026, FUTURE BRIGHT (00703.HK) announced that its wholly-owned subsidiary Chun Ying had entered into two renovation contracts with an independent contractor for its Edo Japanese Restaurant, with lump-sum contract prices of MOP 1,130,000 (approximately HKD 1,096,100) and MOP 13,300,000 (approximately HKD 12,901,000), covering civil and waterproofing works and premium decoration and electrical and mechanical installation works respectively, with the latter expected to be completed in the fourth quarter of 2026. Aggregated under the Listing Rules, the two contracts constitute a discloseable transaction exempt from the circular and shareholders' approval requirements.

Tag： FUTURE BRIGHT 00703.HK Renovation Contract

21:28

[ DL HOLDINGS GP (01709.HK): Bitcoin Mining Business Produces 506.228 BTC in Aggregate, with 405 BTC Sold for Approximately USD 29.98 Million ] On September 3, 2026, DL HOLDINGS GP (01709.HK) announced that its Bitcoin mining business had produced an aggregate of 506.228 Bitcoins since commencing on November 12, 2025, with 405.00 Bitcoins sold at an average price of approximately USD 74,021 each for approximately USD 29.98 million in realized value, and 101.228 Bitcoins still held as of September 2, 2026. The average electricity cost per Bitcoin has declined from a cumulative approximately USD 54,500 to approximately USD 50,000 in August 2026, and the group expects to produce approximately 240 to 264 Bitcoins during the remaining period ending December 31, 2026; the figures have not been audited or reviewed by the company's auditors.

Tag： DL HOLDINGS GP 01709.HK Business Development

21:26

[ SBP GROUP (01177.HK): FDA Approves IND Application for Self-Developed Class 1 Drug TQB6426 "GPC3 ADC" for Advanced Malignant Tumors ] On September 3, 2026, SBP GROUP (01177.HK) announced that TQB6426, a national Class 1 innovative drug and a GPC3-targeting antibody-drug conjugate independently developed by its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd., had received IND approval from the US FDA for advanced malignant tumors. GPC3 is highly expressed in hepatocellular carcinoma and no GPC3-targeting ADC has been approved worldwide; the group will accelerate the Phase I clinical trial to evaluate the drug's safety, tolerability, pharmacokinetic profile and preliminary efficacy.

Tag： SBP GROUP 01177.HK R&D Progress

Scan QR Code

Download App